China’s Medical Device Journey Abroad in 2026: M&A, Going Global and Safety | Includes 240+ Reports and Data Collection Download

Full article link: https://tecdat.cn/?p=46017 Original source: Tuoduan Douyin account @Tuoduan tecdat Cover:

​

About the Analyst Here, we sincerely thank Kaizong Ye for her contributions to this article. She completed her master’s degree at Shanghai University of Finance and Economics, focusing on statistics and healthcare industry research. Has 10 years of experience in data modeling and market research in the medical industry.

Abstract

Chinese abstract: This article answers the following core questions: 1. What are the global healthcare industry M&A trends in 2025? 2. How is the market structure and niche segments of China’s medical device exports going global? 3. What are the main cybersecurity threats facing the healthcare industry in 2026? 4. What are the core opportunities and challenges for medical device companies going global? 5. What strategies can companies implement in response? Abstract：This paper answers the following core questions: 1. What are the trends of global healthcare M&A in 2025? 2. What is the market pattern and segment performance of China’s medical device overseas expansion? 3. What are the main cybersecurity threats facing the healthcare industry in 2026? 4. What are the core opportunities and challenges for medical device enterprises going overseas? 5. What actionable strategies can enterprises adopt?

Introduction

The global healthcare industry is undergoing unprecedented transformation, with domestic volume-based procurement policies continuously deepening, medical device prices dropping by an average of 66.1%, and profit margins for local companies being greatly squeezed, making overseas an inevitable choice. Meanwhile, global medical industry M&A transactions have exploded, cybersecurity threats are becoming increasingly severe, and multiple factors intertwining pose significant challenges to corporate strategic decisions.

This article’s insights are based on the article “Toubao Research Institute: China’s Medical Device Journey Abroad: After the Volume-Based Procurement Storm, Medical Device Prices in China Plummeted by 66.1%, Can Going Global Find New Growth Points for Medical Device Companies?” and the Health-ISAC: 2026 Global Healthcare Industry Threat Landscape Report, along with data from 240+ healthcare industry research reports at the end of the article. The full report data charts and a collection of 240+ latest reference reports at the end have been shared with the member group. Click to read the original text to view the full content, and joining the group grants unlimited packages of 18,000+ industry-wide reports Download Industry resource matching, exclusive expert Q&A privileges, as well as personalized data services and in-depth report writing, enabling collaboration and growth with professionals from 900+ vertical industries.

Core conclusion

1. In 2025, global medical M&A will explode, with biopharmaceutical M&A value increasing by 154% year-on-year and medical devices up 64%. Large deals are accelerating industry consolidation.
2. China’s medical device exports show a tripartite balance of Europe, America, and Asia, with the three major markets together accounting for over 88%, and emerging markets in Southeast Asia emerging as new growth engines.
3. Overseas diversification is significant in niche segments: low-value consumables lead with cost advantages, accounting for 54.23% of overseas revenue, while high-value consumables are limited by technology and channels, with a penetration rate of only 16%.
4. By 2026, AI-powered attacks will become the leading cyber threat in the healthcare industry. Qilin has replaced Lockbit as the top ransomware gang, with hospitals being the hardest attack zone, accounting for 49.6%.
5. Enterprises going global must simultaneously grasp the gap in profit margins and industry innovation opportunities, focusing on two core challenges: strict overseas registration and differences in sales models.

1. Accelerated mergers and integrations in the global healthcare industry

By 2025, the global medical industry is expected to achieve leapfrog growth in M&A transactions, entering a new stage of industry consolidation. Leading companies rapidly gain technology, channels, and market share through mergers and acquisitions, with industry concentration continuously increasing. See Infographic 1 of the global medical industry M&A scale comparison

Comparison of Global M&A Scale in the Medical Industry Infographic 1 Comparison of Global M&A Scale in the Medical Industry Infographic 1 PDF template has been shared with the member group. In terms of deal size, the biopharmaceutical sector performed the best, with M&A value expected to reach $201.2 billion in 2025, a year-on-year increase of 154%. The largest deal was Kimberly-Clark’s $48.7 billion acquisition of Kenvue. M&A in the medical device sector reached $58.8 billion, up 64% year-on-year, with the largest deal being Abbott’s $21 billion acquisition of Exact Sciences.

See Polygon Bar Chart 1 for the growth of biomedical and medical device M&A transactions in the medical industry. Comparison of Polygon Bar Chart 1 for the growth of M&A transactions in the medical industry. Polygon Chart 1 for the growth of M&A transactions in the medical industry. Data EXCEL and PDF templates of charts have been shared with the member group. Interpretation: The high growth in the biopharmaceutical sector is mainly driven by rising costs in innovative drug R&D and the need for complementary pipelines, while the medical device sector is driven by digital transformation and high-end technology integration. Action recommendations for the target audience: Industrial capital should focus on mergers and acquisitions between innovative drug pipelines and high-end medical device companies; SMEs can focus on technological breakthroughs in niche sectors and seek opportunities to be acquired by leading companies; Overseas entrepreneurs can pay attention to market gaps after mergers and acquisitions to enter the market Localization Service Sector. Alliance deals in the biopharmaceutical sector are also active, with Chinese pharmaceutical companies playing an important role in global cooperation. In the 2025 global biopharmaceutical TOP5 alliance deals, Chinese companies will occupy three spots. Hengrui Medicine’s $12.5 billion partnership with GSK is the largest deal of the year, followed closely by Innovent Biologics’ $11.4 billion partnership with Takeda.

See Medical Industry Biopharmaceutical TOP Alliance Trading Infographic 2 Medical Industry Biopharmaceutical TOP Alliance Trading Infographic 2 Medical Industry Biopharmaceutical TOP Alliance Trading Infographic 2 PDF template of the chart has been shared with the member group. Interpretation: Chinese pharmaceutical companies, leveraging their R&D cost advantages and innovation capabilities, are gradually shifting from technology introduction to technology export, significantly enhancing their global competitiveness. Action recommendations for the target audience: pharmaceutical companies can strengthen cooperation with international giants and rapidly expand global markets through licensing to go global; Investors may focus on innovative pharmaceutical companies with international pipelines; Industrial capital can enter the CRO/CDMO sector, benefiting from the growing global demand for R&D outsourcing.

Related articles

Original link: https://tecdat.cn/?p=41208

2. The Landscape of China’s Medical Device Overseas Market

The continuous advancement of domestic volume-based procurement policies has greatly compressed the profit margins of medical device companies, making overseas expansion a core strategy for seeking new growth. In 2023, China’s medical device export market showed clear regional distribution characteristics.

See Medical Industry China Medical Device Export Market Distribution Information Chart 3 Medical Industry China Medical Device Export Market Distribution Information Chart 3 Medical Industry China Medical Device Export Market Distribution Information Chart 3 Chart PDF template has been shared with member groups. In terms of intercontinental distribution, the Asian market holds the highest share, reaching 34.45%, with Southeast Asia growing the fastest. The signing of the RCEP agreement has facilitated the entry of Chinese medical devices into the Southeast Asian market. North America accounts for 27.92%, Europe for 26.06%, and Europe and America remain the main consumer markets for high-end medical devices. South America, Africa, and Oceania have small market shares, but huge growth potential.

See the Medical Industry Circular on the Proportion of China’s Intercontinental Medical Device Export Value Roundabout. Figure 2 The Medical Industry Circular on the Proportion of China’s Intercontinental Medical Device Export Value Chart 2 The data EXCEL and PDF templates of charts have been shared with our member group. Interpretation: European and American markets have high entry barriers but large profit margins. Emerging markets such as Southeast Asia are relatively easy to access and grow rapidly. Companies can adopt a dual-track strategy of “high-end breakthrough + emerging penetration.” Action recommendations for the target audience: High-end medical device companies should focus on the European and American markets and complete FDA/CE certification ahead of schedule; Mid- and low-end enterprises will prioritize expanding into emerging markets such as Southeast Asia and Africa; Cross-border e-commerce practitioners can build localized sales platforms to serve the needs of small and medium-sized medical institutions.

3. Differentiation in China’s medical device niche segment going global

The performance of going overseas varies significantly across different segments, mainly due to differences in technical barriers, market demand, and competitive landscape. See Infographic 4 for the comparison of overseas performance in medical industry sub-sectors

Comparison of overseas performance in medical industry segments: Infographic 4 Comparison of overseas performance in medical industry sub-sectors Infographic 4: PDF template of chart has been shared with member groups. The low-value consumables sector performed best overseas, with average overseas revenue accounting for 54.23% in 2022, mainly benefiting from China’s comprehensive supply chain system and cost advantages, with products such as disposable gloves, syringes, and medical dressings occupying major global market shares. The medical device sector ranks second, with overseas revenue accounting for 38.8% of the average revenue. Products such as monitors, ventilators, and ultrasound equipment have gained global recognition for their high cost-effectiveness. The in vitro diagnostics track accounts for an average of 26% of overseas revenue, with chemiluminescence, molecular diagnostics, and other products gradually opening up international markets. The high-value consumables sector faces the greatest challenge in going global, with average overseas revenue accounting for only 16%, mainly limited by technical barriers, clinical data requirements, and high channel construction costs.

See the gray background ratio bar chart for overseas revenue proportion of China’s medical device sub-tracks in the medical industry 3 . The gray background ratio bar chart for the overseas revenue proportion of China’s medical device sub-tracks in the medical industry 3 . The data EXCEL and PDF templates of charts have been shared with members. Interpretation: Low-value consumables have entered a mature stage of overseas expansion, medical equipment is in a rapid growth phase, while in vitro diagnostics and high-value consumables are still in the early stages, with the greatest potential for future growth. Action recommendations for corresponding groups: low-value consumables companies can enhance product added value through brand upgrades; Medical equipment companies are strengthening after-sales service systems to enhance customer loyalty; High-value consumables companies should prioritize international multicenter clinical trials to accumulate clinical data.

4. Opportunities and Challenges for Chinese Medical Devices Going Global

Chinese medical device companies facing a rare historical opportunity going global also need to address multiple challenges. See the Framework of Opportunities and Challenges for Going Global in the Medical Industry Infographic 5 Framework Infographic 5 The PDF template of the chart for Opportunities and Challenges in the Medical Industry Going Global has been shared with the member group. The core opportunities are mainly reflected in two aspects: first, the huge profit gap between domestic and international markets. The average price reduction in domestic volume-based procurement is 66.1%, while overseas markets generally price higher prices, allowing the same product to achieve higher profits abroad; Second, the wave of innovation in China’s medical device industry is rising. As of 2023, the National Medical Products Administration has approved 250 innovative medical devices for market launch, 77% of which are domestically produced. The improvement in technological strength has provided solid support for going global. Core challenges are equally prominent: First, product registration in overseas developed countries is strict, FDA PMA certification and EU MDR regulations are stringent, approval cycles are lengthy, and costs are high; Second, overseas sales models differ greatly from domestic ones. European and American markets mainly use the GPO centralized procurement model, requiring companies to have strong academic promotion and channel building capabilities. Interpretation: Opportunities outweigh challenges. As long as companies can overcome the two major bottlenecks of registration and channels, they can gain broad development space in overseas markets. Action recommendations for target groups: Companies should plan for overseas registration in advance and form professional registration teams; Cooperate with local distributors to quickly build sales channels; Strengthen academic promotion and enhance brand awareness.

5. Cybersecurity Threat Landscape in the Medical Industry in 2026

With the acceleration of digital transformation in the healthcare industry, cybersecurity threats have become increasingly severe and have become a major factor affecting normal business operations and patient safety. By 2025, Qilin will replace Lockbit as the most attacked ransomware group in the healthcare industry, launching 77 attacks throughout the year — more than three times the number in 2024. INC Ransomware ranked second with 50 attacks, while SAFEPAY, as an emerging group, saw its attack volume grow from 3 in 2024 to 21 in 2025, a growth rate of more than sixfold. See the medical industry ransomware gang attack scale chart 4

Healthcare Industry Ransomware Gang Attack Quantity Scale Chart 4 Medical Industry Ransomware Gang Attack Scale Chart 4 Data EXCEL and PDF chart templates have been shared with the member group. Interpretation: Ransomware remains the largest cybersecurity threat in the healthcare industry, with emerging gangs emerging and increasingly diverse attack methods. Action recommendations for corresponding groups: Medical institutions and medical device companies should regularly conduct cybersecurity vulnerability scans; Deploying endpoint detection and response systems; Develop data backup and recovery plans. Looking ahead, in 2026, AI-powered attacks will become the leading cyber threat in the healthcare industry, with ransomware deployment ranking second, and attention to third-party and zero-day vulnerabilities remaining high.

See Bubble Chart 5 of Changes in Healthcare Industry Network Threat Attention Rankings Bubble Chart 5 Bubble Chart 5 Bubble Chart of Changes in Medical Industry Network Threat Awareness Rankings Bubble Chart 5 Data EXCEL and PDF templates of charts have been shared with member groups. Interpretation: The development of AI technology has made attacks more precise and efficient. Traditional security protection methods are no longer sufficient, so enterprises need to adopt AI-driven security solutions. Action recommendations for corresponding groups: enterprises should increase investment in AI security technologies and enhance threat detection and response capabilities; Enhance employee security training to guard against AI-generated phishing emails and social engineering attacks; Establish an AI security governance system and standardize the use of AI technologies. In terms of attack targets, hospitals and healthcare institutions are the absolute hardest hit areas for ransomware attacks, accounting for 49.6%, medical clinics for 25.7%, and medical equipment for 9.3%, making them emerging targets. See chart 6 of the proportion of semicircle area in the healthcare industry ransomware attack sub-field. Figure 6 of the proportion of semicircle area in the medical industry ransomware attack sub-field. Figure 6 of the proportion of semicircle area in the healthcare industry ransomware attack sub-field. Figure 6 Data EXCEL and PDF chart templates have been shared with the member group. Interpretation: Hospitals hold large amounts of sensitive patient data, and business disruptions can have serious life-threatening consequences, making them prime targets for attackers. Medical devices are becoming a new entry point for attacks due to numerous security vulnerabilities in legacy systems. Action recommendations for corresponding groups: hospitals should strengthen network segmentation and isolate medical equipment from office networks; Timely update equipment firmware and patch security vulnerabilities; Purchase cybersecurity insurance to reduce losses caused by attacks.

6. Three practical matters

1. Research the medical device registration requirements and sales models in target markets, focusing on the latest regulatory changes in Southeast Asia and Europe, and formulate targeted overseas registration plans.
2. Conduct comprehensive cybersecurity risk assessments, identify security vulnerabilities in medical equipment and information systems, and establish data backup and emergency response mechanisms.
3. Analyze the competitive landscape of overseas markets in its niche to identify differentiated competitive points, such as developing cost-effective customized products for emerging markets.

7. Core Risk Alerts and Response Plans

1. Overseas registration risks: FDA/CE certification cycles are long and costly, which may cause delays in product launch. Response plan: Start the registration process 1–2 years in advance and hire local professional registration agencies for assistance; Prioritize applying for relatively simple certification paths such as 510K. The community can provide interpretation of registration regulations for major global markets and liaison services with professional institutions.
2. Cybersecurity risks: Ransomware attacks may cause business disruptions and data leaks, resulting in hefty fines and reputational damage. Response measures: Deploy multi-layered security protection systems and conduct regular security drills; Purchase cybersecurity insurance. The community can provide cybersecurity solution recommendations and emergency response support.
3. Patent infringement risk: Patent protection in overseas markets is strict, and you may face patent litigation. Response Plan: Conduct comprehensive patent searches and analyses before going global; Patent protection applications for target markets; Avoid patent risks through cross-licensing. The community can provide patent search and analysis services.

8. Core Recommendation Report

Classified by user demand scenarios, the following core reports are selected:

• Overseas Entrepreneurs: Key Recommendation “Toubao Research Institute: China’s Medical Device Going Global: After the Volume-Based Procurement Storm, Medical Device Prices in China Plummeted by 66.1%, Can Going Global Find New Growth Points for Medical Device Companies?” “, Report Value: A comprehensive analysis of the market landscape, performance in niche tracks, and successful cases of Chinese medical devices going global.
• Industry Capital: Highly recommends the “Evaluate: 2025 Global Biomedicine and Medical Technology Transaction Panorama White Paper,” report value: provides a detailed overview of global medical industry M&A and alliance transaction trends, providing investment decision-making references.
• Head of Corporate Security: Highly recommends the “Health-ISAC: 2026 Global Healthcare Industry Threat Landscape Report,” which offers an in-depth analysis of the main cybersecurity threats facing the healthcare industry and response strategies.
• AI healthcare professionals: Highly recommended: “2026 AI Healthcare Industry Special Report: Smart Medical Devices, Surgical Robots, Brain-Computer Interfaces, Wearable Devices.” Report value: A comprehensive interpretation of AI application scenarios and market prospects in healthcare.

Summary

1. The global healthcare industry is at a critical juncture of integration and transformation, with explosive growth in mergers and acquisitions, and the growing status of Chinese pharmaceutical companies in global cooperation.
2. China’s medical device overseas expansion has entered a new stage, with a clear market structure and significant differentiation in niche segments. Low-value consumables lead the way, while high-value consumables have the greatest future growth potential.
3. Enterprises going global need to simultaneously grasp the gap in profit margins and industry innovation opportunities, focusing on breaking through two major bottlenecks: overseas registration and sales channels.
4. By 2026, AI-powered attacks will become the primary cyber threat in the healthcare industry, with hospitals being the hardest hit areas. Companies need to strengthen their cybersecurity protection systems.
5. It is recommended that companies adopt an “high-end breakthrough + emerging penetration” overseas strategy, while also paying close attention to cybersecurity risks to achieve sustainable development.

This article lists charts and figures

Opportunities and Challenges in the Medical Industry Going Global Framework Infographic 5.pdf Comparison of Overseas Performance of Medical Industry Sub-sectors in the Overseas Sector 4.pdf Distribution of China’s Medical Device Export Market Infographic in the Medical Industry 3.pdf Biopharmaceutical TOP Alliance Trading Infographic 2.pdf Comparison of Global M&A Scale in the Medical Industry Infographic Semicircle Area Proportion of Ransomware Attack Subfields in the Medical Industry Figure 6 Data .csv Semicircle Area Proportion of Ransomware Attack Subfields in the Medical Industry Chart 6.pdf Bubble Chart 5 Data .csv Bubble Chart of Changes in Cybersecurity Threat Awareness Rankings in the Medical Industry 5.pdf Healthcare Industry Ransomware Gang Attack Quantity Scale Chart 4 Data .csv Healthcare Industry Ransomware Gang Attack Quantity Scale Chart 4.pdf Gray Background Proportion Bar Chart 3 Data of Overseas Revenue Proportion of China’s Medical Device Sub-Track in the Medical Industry 3 Data .csv Gray Background Proportion Bar Chart of Overseas Revenue Proportion in China’s Medical Device Sub-Track in the Medical Industry 3.pdf Chart 2 of the Proportion of China’s Intercontinental Medical Device Export Value in the Medical Industry Chart .csv Chart 2.pdf Comparison of Growth in Biopharmaceutical and Medical Device M&A Transactions in the Medical Industry and Polygon Bar Chart 1 Data .csv Comparison of biopharmaceutical and medical device M&A transaction growth in the medical industry 1.pdf the polygon bar chart

Table of Reference Reports (PDF) within this topic

The 2026 Global Healthcare Industry Threat Landscape Report -Health-ISAC.pdf

2026–06–01 08:25

China’s Medical Device Journey Abroad: After the volume-based procurement storm, medical device prices in China have plummeted by 66.1%. Can going global find new growth points for medical device companies? .pdf

2026–05–27 15:03

Lüshi Station: 2026 Medical and Health Laws and Regulations Bring .pdf to a Century

2026–05–23 13:44

Mercer: 2026 Healthcare Industry Innovation Investment Value Proposition Report .pdf

2026–05–22 16:33

Tsinghua University & Asia-Pacific Medical Technology Association: 2026 Research Report on the Application and Development of Artificial Intelligence Medical Devices.pdf

2026–05–20 15:35

Sullivan: .pdf of the 2026 China Ophthalmic Medical Equipment White Paper

2026–05–20 15:32

_Qualtrics: 2026 Global Healthcare Industry Experience Trends Report .pdf

2026–05–20 15:27

Innovative Medical Devices Special: Brain-Computer Interface Industry Series 3: The International Standard Led by China Officially Released, marking the first year of the brain-machine industry moving from a laboratory to large-scale industrial application.pdf

2026–05–19 15:17

2025 Global Biopharmaceutical and Medical Technology Trading Panorama White Paper — 30 pages .pdf

2026–05–17 09:59

Nvidia: 2026 Healthcare and Life Sciences Industry AI Development Status and Trends Report .pdf

2026–05–15 14:29

Huachuang Medical Devices Essay Series 15: Surgical Robot Special: In the first half, foreign capital led the creation of an outstanding business model; in the second half, the rise of domestic brands is expected to reshape the .pdf

2026–05–08 14:44

2026 Medical Aesthetics User White Paper — Chengdu Medical Aesthetics Association .pdf

2026–05–07 15:12

2025 Global Pet Healthcare Market Insights Report — Midodo .pdf

2026–05–07 15:11

Perimattic: 2025 AI Precision Medicine Research Report: Artificial Intelligence-Driven Scaling .pdf of Personalized Treatment

2026–05–07 15:05

2026 Clinical Decision-Making White Paper in the Era of Generative AI — Insights into Emerging Behavioral Signals from European Healthcare Practitioners.pdf

2026–05–06 09:10

2026 Medical Device Trend Report Writing Guide Trial — .pdf of the China Medical Device Industry Association

2026–04–30 15:23

Shuoyuan Consulting: 2026 China Primary Medical Public Service Industry Market Research Report .pdf

2026–04–23 15:45

Medical investment and outcomes: .pdf in Central and Eastern Europe

2026–04–23 15:37

2026 White Paper on the New Journey of China’s Medical Device Globalization Rising in Southeast Asia — EDBL.E.K. Consulting .pdf by the Singapore Economic Development Board

2026–04–22 15:29

China Re Life: 2026 Health and Medical Big Data Empowerment of Commercial Insurance Application Research Report (Refined Edition) .pdf

2026–04–22 15:27

China Re Life: 2026 Health and Medical Big Data Empowerment of Commercial Insurance Application Research Report (Refined Edition) .pdf

2026–04–22 15:21

Huachuang Medical Devices Essay Series 14: Ambu Business Update: The Global Leader in Disposable Endoscopes Enters a New Development Stage .pdf

2026–04–22 15:15

National Obstetrics Specialty Medical Quality Control Center: 2025 National Medical Service and Quality Safety Report (Obstetrics) .pdf

2026–04–20 15:23

Nucleic Acid Tetrahedral Blue Book — Creating Medical & Sullivan .pdf

2026–04–16 16:16

2026 Medical Productivity Restructuring Report — Quantitative Analysis of the Application Prospects of AI, Robotics, and Quantum Technology (English Version) .pdf

2026–04–14 15:48

Medical Technology In-Depth Report Series: Surgical Robots: A Reflection of Intuitive Surgery Over 30 Years of Development, .pdf the Global Commercialization of Domestic Surgical Robots

2026–04–14 15:41

Hunan Province Biomedicine and Medical Device Industry Working Group: 2026 Enterprise-Benefiting Policy Pocket .pdf

2026–04–10 15:38

Minglue Technology: AI Dialogue and Consumer Decision Research Report — Medical Health Section .pdf

2026–04–07 15:42

Artery Think Tank: .pdf of the global healthcare sector investment and financing monthly report for February 2026

2026–04–06 17:09

Shanghai Kechuang Bank: 2026 China Medical and Health Industry Capital Market Trend Report .pdf

2026–04–05 12:27

Pharmaceutical and Health Industry Research: Special Topic on Price Increases in the Medical Industry Chain — Opportunities for Price Increases for APIs and Consumables, Industry Prosperity Expected to Rebound .pdf

2026–04–03 15:12

Data fusion stimulates incremental value .pdf in healthcare and healthcare

2026–04–01 15:28

2025 Intelligent-Driven Healthcare Ecosystem: Comprehensive Optimization Report .pdf from Data to Decision

2026–03–30 15:22

Citibank: 2026 China Silver Economy: Healthcare and Insurance Report (English Version) .pdf

2026–03–29 09:03

Interpretation Report on the Pharmaceutical and Biotechnology Industry 15th Five-Year Plan Outline — People-Oriented, Systematic Healthcare Upgrading .pdf

2026–03–22 16:34

Medical Industry AI Special Report (Part 1): Overseas Edition, the time is right to ride the waves and set sail for the .pdf of medical services

2026–03–21 19:23

China IoT Pharmaceutical Logistics and Supply Chain Branch: 2026 Medical Institution Traditional Chinese Medicine Formulations Market Analysis Report .pdf

2026–03–20 15:41

Compilation of Medical Quality Management and Control Indicators (8.0) .pdf

2026–03–19 15:35

PwC: 2026 Research Report on the Transformative Power of Generative AI in Healthcare (English Version) .pdf

2026–03–15 16:28

Technology creates a bright vision: Gaoshi Medical upgrades strategy, climbing new heights in ophthalmic medical device .pdf

2026–03–13 15:40

Medical Consumables Industry Report — Promising Prospects for Domestic PFA .pdf

2026–03–13 15:37

Medical Mosaic: The Growing Importance of AI in Revenue Cycle Management .pdf the Market

2026–03–12 15:58

2025 China Internet Healthcare Industry Consumer Behavior Survey Data — iiMedia Research .pdf

2026–03–11 16:07

-DrakeStar.pdf of the Q4 2025 Telemedicine Report (English).

2026–03–10 16:29

AI and the Future of Billing in the Healthcare Industry: Breakthroughs for Suppliers and Investors — William Blair.pdf

2026–03–05 14:49

Outlook for Global M&A Trends in 2026: Healthcare .pdf

2026–03–04 21:40

National Data Administration: 2025 “Data Element ×” Competition National Finals Award-Winning Project Case Collection — Medical Security Track .pdf

2026–03–02 16:10

Weining Health: 2025 Medical Artificial Intelligence Annual Report .pdf

2026–02–28 16:04

Yiwang Education: 2025 Profile of Part-time PhD Applicants in the Medical and Health Field: Big Data Insight Report .pdf

2026–02–28 16:02

Looking at Industry Investment Opportunities in Equipment Bidding for 2026 — The Equipment Inflection Point Clearly Uptrends Are Clear, and Medical New Technologies .pdf Flourishing

2026–02–26 15:52

National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) — .pdf by the National Healthcare Security Administration

2026–02–25 14:50

Telemedicine: Review of 2025 and Outlook for 2026 .pdf

2026–02–23 09:18

AON A-On Think Tank: 2026 Global Medical Trends Report .pdf

2026–02–14 15:48

CAICT: Blue Book on the Intelligent Medical Equipment Industry (2025) .pdf

2026–02–12 14:28

The pharmaceutical and biotech industry looks at investment opportunities in 2026 through equipment bidding — the equipment inflection point is clearly upward, and new medical technologies are thriving .pdf

2026–02–12 14:21

Healthcare Industry Innovation Chain Series — The prosperity of China’s innovative drug R&D is gradually improving, and the early research industry chain may significantly benefit .pdf

2026–02–12 14:21

In-depth Report on Medical Consumables & Offline Pharmacy Industry — Finding Certainty .pdf in Differentiation

2026–02–12 14:21

Medical Device Innovation Series Industry Report (I): Surgical Robot Five Questions and Five Answers .pdf

2026–02–12 14:21

Final.pdf the 2026 Healthcare and Life Sciences Industry Outlook

2026–02–11 15:32

Healthcare Industry: Global Risk Assessment of COVID-19–9th Edition .pdf

2026–02–11 15:26

Innovative Medical Device Review Series (4): The “Braveman’s Game” in Tumor Genetic Testing (Part 1) .pdf

2026–02–09 14:20

Special Report on Home Medical Devices (I): Health Monitoring & Respiratory Therapy .pdf

2026–02–08 09:56

Huaxi Securities — In-depth Research Report on the Small Nucleotide Drug Industry: The Rise and Challenges of the RNA Precision Medicine Era .pdf

2026–02–08 09:56

China’s Private Medical Services: Weathering the Cold Winter, Waiting for the .pdf of Spring

2026–02–06 16:42

2025 Global Healthcare Industry Capital Report .pdf

2026–02–04 16:40

Issue 139 — Ye Yanxin & Song Liheng — “Zhiqi AI New Journey: From FastGPT Practice to Exploring Medical Model Interpretability.” pdf

2026–02–04 16:37

Oral Medical Institution Advertising Compliance Guidelines (2025) .pdf

2026–02–01 13:30

AI Healthcare Industry Special Report — AI Reshaping Healthcare, From Scenario Implementation to Monetization Discussions.pdf

2026–02–01 13:27

“The Road to Rebalancing” Series Part Two: Stabilizing the Inflation Path from Medical Service Price Hikes .pdf

2026–02–01 13:26

Changjiang Securities: In-depth Overseas Expansion of Medical Devices (Part 2) Review of Xisen Meikang — Deep Overseas Cultivation, Local Foundation .pdf

2026–02–01 13:25

Everbright Securities: Special Report on the AI Healthcare Industry — AI Reshaping Healthcare, From Scenario Implementation to Monetization Discussion .pdf

2026–02–01 13:25

In-depth Medical Device Overseas Expansion (Part 2) Review of Xisen Meikang — Deep Overseas Cultivation, Local Foundation .pdf

2026–01–30 15:56

Intellectual Property Publisher: .pdf of the 2025 Patent Analysis White Paper on the Healthcare Industry

2026–01–30 15:54

Future Health 7: .pdf of the future healthcare system

2026–01–29 14:29

The Era of Agents 2025: Reshaping the Future of Enterprises Report — Healthcare and Life Sciences Industry .pdf

2026–01–28 16:00

Huachuang Medical Device Exploration Series 11: Brain-Computer Interface Industry: Policy Increase, Clinical Acceleration, Industrialization Enters a Key Stage .pdf

2026–01–28 15:51

Artificial Intelligence Industry Special: OpenAI releases healthcare GPT, ushering in a new era of AI healthcare .pdf

2026–01–27 15:48

Siyu MedTech: .pdf the 2025 Medical Device BD White Paper

2026–01–25 12:39

Shanghai Academy of Social Sciences: AI Medical Governance White Paper (2026 Edition) .pdf

2026–01–24 17:41

Analysis .pdf of China’s biopharmaceuticals, medical equipment, and medical consumables exports and key import markets

2026–01–22 12:06

and 240+ other selected medical and health industry reports have been shared with the member group (join the group for the full directory).